Abstract 059 ADA efficacy at Weeks 26 and 56, % of patients
| Endpoints | Wk | PBO (n = 170) | ADA 40 mg EOW (n = 172) | ADA 40 mg W (n = 157) |
|---|---|---|---|---|
| *p<0.001 v PBO. | ||||
| Remission | 26 | 17 | 40* | 47* |
| 56 | 12 | 36* | 41* | |
| CR-100 | 26 | 27 | 52* | 52* |
| 56 | 17 | 41* | 48* | |
| CR-70 | 26 | 28 | 54* | 56* |
| 56 | 18 | 43* | 49* | |